Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 10, 2013, Pages

  Komissarov, Andrey A ^a   Florova, Galina ^a   Azghani, Ali ^b   Karandashova, Sophia ^a   Kurdowska, Anna K ^a   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UNIVERSITY OF TEXAS AT TYLER   (United States)

Author keywords

Fibrinolytic therapy; Human; Macroglobulin; Pleural injury; Rabbit model; Urokinase

Indexed keywords

ALPHA 2 MACROGLOBULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROUROKINASE; TETRACYCLINE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BIOAVAILABILITY; FIBRINOLYTIC THERAPY; HUMAN; MALIGNANT PLEURA EFFUSION; NONHUMAN; PLASMINOGEN ACTIVATION; PLEURA EMPYEMA; PLEURA FLUID; PNEUMONIA; PRIORITY JOURNAL;

Α-MACROGLOBULIN; FIBRINOLYTIC THERAPY; HUMAN; PLEURAL INJURY; RABBIT MODEL; UROKINASE;

ALPHA-MACROGLOBULINS; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLEURA; RABBITS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; TETRACYCLINES; THROMBOLYTIC THERAPY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84887604096     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00102.2013     Document Type: Article

References (53)

1. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrom botic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 133: 630S-669S, 2008.
2. Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, Varela E, Ruiz E, Fernandez de Sevilla T. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond) 105: 601-607, 2003.
3. Allport LE, Butcher KS. Thrombolysis for concomitant acute stroke and pulmonary embolism. J Clin Neurosci 15: 917-920, 2008
4. Banbula A, Chang LS, Beyer WF, Bohra CL, Cianciolo GJ, Pizzo SV. The properties of rabbit alpha1-macroglobulin upon activation are distinct from those of rabbit and human alpha2-macroglobulins. J Biochem 138: 527-537, 2005.
5. Barrett AJ. Alpha 2-macroglobulin. Methods Enzymol 80: 737-754, 1981.
6. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 133: 709-724, 1973.
7. Borth W. Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 6: 3345-3353, 1992.
8. Bouros D, Tzouvelekis A, Antoniou KM, Heffner JE. Intrapleural fibrinolytic therapy for pleural infection. Pulm Pharmacol Ther 20: 616-626, 2007.
9. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev CD002312, 2008.
10. Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 84: 1216-1234, 1991.
11. Corcoran JP, Hallifax R, Rahman NM. New therapeutic approaches to pleural infection. Curr Opin Infect Dis 26: 196-202, 2013.
12. Decologne N, Kolb M, Margetts PJ, Menetrier F, Artur Y, Garrido C, Gauldie J, Camus P, Bonniaud P. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol 179: 6043-6051, 2007.
13. Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section-a comparison of the antithrombotic properties of three low molecular weight heparins-dalteparin, enoxaparin and tinzaparin. Thromb Haemost 86: 1374-1378, 2001.
14. Feinman RD, Wang D, Windwer SR, Wu K. The role of enzyme lysyl amino groups in the reaction with alpha 2-macroglobulin. Ann NY Acad Sci 421: 178-187, 1983.
15. Feldman SR, Ney KA, Gonias SL, Pizzo SV. In Vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endopro-teases from four different classes. Biochem Biophys Res Commun 114: 757-762, 1983.
16. Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. J Clin Invest 43: 681-695, 1964.
17. Ganrot PO. Variation of the alpha 2-macroglobulin homologue with age in some mammals. Scand J Clin Lab Invest 21: 177-181, 1968.
18. Gonias SL, Balber AE, Hubbard WJ, Pizzo SV. Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. Biochem J 209: 99-105, 1983.
19. Harada S, Dannenberg AM Jr, Vogt RF Jr, Myrick JE, Tanaka F, Redding LC, Merkhofer RM, Pula PJ, Scott AL. Inflammatory mediators and modulators released in organ culture from rabbit skin lesions produced in vivo by sulfur mustard III Electrophoretic protein fractions, trypsin-inhibitory capacity, alpha 1-proteinase inhibitor, and alpha 1and alpha 2-macroglobulin proteinase inhibitors of culture fluids and serum. Am J Pathol 126: 148-163, 1987.
20. Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. Adv Ther 11: 43-51, 1994.
21. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, Yanez D, Martinez M, Navar J. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 18: 1413-1418, 1990.
22. Harpel PC, Mosesson MW. Degradation of human fibrinogen by plasma alpha2-macroglobulin-enzyme complexes. J Clin Invest 52: 2175-2184, 1973.
23. Hedstrom L. Serine protease mechanism and specificity. Chem Rev 102: 4501-4524, 2002.
24. Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 262: 199-210, 1988.
25. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 2: 566-574, 1994.
26. Idell S. The pathogenesis of pleural space loculation and fibrosis. Curr Opin Pulm Med 14: 310-315, 2008.
27. Idell S, Azghani A, Chen S, Koenig K, Mazar A, Kodandapani L, Bdeir K, Cines D, Kulikovskaya I, Allen T. Intrapleural low-molecularweight urokinase or tissue plasminogen activator vs. single-chain uroki-nase in tetracycline-induced pleural loculation in rabbits. Exp Lung Res 33: 419-440, 2007.
28. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 144: 187-194, 1991.
29. Idell S, Jun NM, Liao H, Gazar AE, Drake W, Lane KB, Koenig K, Komissarov A, Tucker T, Light RW. Single-chain urokinase in empyema induced by Pasturella multocida. Exp Lung Res 35: 665-681, 2009.
30. Idell S, Mazar A, Cines D, Kuo A, Parry G, Gawlak S, Juarez J, Koenig K, Azghani A, Hadden W, McLarty J, Miller E. Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits. Am J Respir Crit Care Med 166: 920-926, 2002.
31. Idell S. Update on the use of fibrinolysins in pleural disease. Clin Pulm Med 12: 184-190, 2005.
32. Karandashova S, Florova G, Azghani AO, Komissarov AA, Koenig K, Tucker TA, Allen TC, Stewart K, Tvinnereim A, Idell S. Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacer-bates tetracycline-induced pleural injury in rabbits. Am J Respir Cell Mol Biol 48: 44-52, 2013.
33. Kim HS, Patra A, Paxton BE, Khan J, Streiff MB. Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy vs. thrombolysis alone in upper and lower extremity deep vein thrombosis. Cardiovasc Intervent Radiol 29: 1003-1007, 2006.
34. Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem 286: 41949-41962, 2011.
35. Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S. Regulation of intrapleural fibrinolysis by urokinase-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 297: L568 -L577, 2009.
36. Komissarov AA, Stankowska D, Krupa A, Fudala R, Florova G, Florence J, Fol M, Allen TC, Idell S, Matthay MA, Kurdowska AK. Novel aspects of urokinase function in the injured lung: role of 2macroglobulin. Am J Physiol Lung Cell Mol Physiol 303: L1037-L1045, 2012.
37. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TE, Woodhead MA, Lane DJ, Darbyshire JH, Davies RJUK. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 352: 865-874, 2005.
38. Midde KK, Batchinsky AI, Cancio LC, Shetty S, Komissarov AA, Florova G, Walker KP, III, Koenig K, Chroneos ZC, Allen T, Chung K, Dubick M, Idell S. Wood bark smoke induces lung and pleural plasminogen activator inhibitor 1 and stabilizes its mRNA in porcine lung cells. Shock 36: 128-137, 2011.
39. Nilsson T, Wallen P, Mellbring G. In Vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 33: 49-53, 1984.
40. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, Sterling K, Comerota A. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol 19: 521-528, 2008.
41. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, Juhan-Vague I. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 8: 1352-1356, 1995.
42. Pizzo SV, Rajagopalan S, Roche PA, Fuchs HE, Feldman SR, Gonias SL. Specificity of alpha 2-macroglobulin covalent cross-linking for the active domain of proteinases. Biol Chem Hoppe Seyler 367: 1177-1182, 1986.
43. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee YC, Hedley EL, Crosth-waite N, Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 365: 518-526, 2011.
44. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 90: 2103-2114, 1994.
45. Salvesen GS, Sayers CA, Barrett AJ. Further characterization of the covalent linking reaction of alpha 2-macroglobulin. Biochem J 195: 453-461, 1981.
46. Schved JF, Gris JC, Gilly D, Joubert P, Eledjam JJ, d'Athis F. [Fibrinolytic activity in traumatic hemothorax fluids]. Ann Fr Anesth Reanim 10: 104-107, 1991.
47. Sisson TH, Simon RH. The plasminogen activation system in lung disease. Curr Drug Targets 8: 1016-1029, 2007.
48. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 264: 11539-11542, 1989.
49. Stefanutti G, Ghirardo V, Barbato A, Gamba P. Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. Surgery 148: 589-594, 2010.
50. Straight DL, Hassett MA, McKee PA. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin. Biochemistry 24: 3902-3907, 1985.
51. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab 13: 66-74, 2002.
52. Tamamizu S, Miyake Y, Ito T, Sinohara H. Changes in trypsin-binding properties and conformation of rabbit alpha-2-macroglobulin on reaction with methylamine. J Biochem 105: 898-904, 1989.
53. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 175: 33-39, 1988.